TabletsMRP Under Process
Official PMBI MRP is being updated for catalog code 2661.
Locate Jan Aushadhi KendraClinical Overview
Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Take orally with water, once daily (for doses <= 300 mg) or divided twice daily (for doses > 300 mg), preferably before meals. Complete the full prescribed course.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Hyperprolactinemia (galactorrhea, amenorrhea, breast pain), insomnia, anxiety, somnolence, constipation, nausea. Rare/Severe: QT prolongation and torsades de pointes, tardive dyskinesia, neuroleptic malignant syndrome, and seizures.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Contraindicated in prolactin-dependent tumors (prolactinoma, breast cancer) and pheochromocytoma. Caution in patients with bradycardia, hypokalemia, or congenital QT prolongation. Dose reduction required in renal impairment.
Schedule H (Prescription Required)
This medication is scheduled under statutory drug regulatory frameworks (CDSCO / Drugs & Cosmetics Rules). Dispensing requires a valid medical prescription from a registered medical practitioner. Self-medication or unsupervised dosage adjustment carries significant clinical risks.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, clinical diagnosis, or treatment recommendations. Always consult a registered medical practitioner or qualified pharmacist before initiating, modifying, or substituting any medication regimen.
Amisulpride Tablets 50mg
Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.
Amisulpride Tablets 100 mg
Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.
Amisulpride Tablets 200 mg
Amisulpride is a substituted benzamide atypical antipsychotic. It acts with high selectivity as an antagonist at presynaptic and postsynaptic dopamine D2 and D3 receptors in the limbic system, with zero affinity for 5-HT, adrenergic, cholinergic, or histaminergic receptors. At low doses (50-300 mg), it preferentially blocks presynaptic autoreceptors, facilitating dopamine release and improving negative and cognitive symptoms; at higher doses (400-800 mg), it blocks postsynaptic D2 receptors to control positive psychotic symptoms. Indicated for schizophrenia with acute psychotic episodes and predominant negative symptoms.
Amisulpride Tablets 300mg
Amisulpride Tablets (300mg) is a substituted benzamide atypical antipsychotic and dopamine D2/D3 receptor antagonist on the WHO Model List framework. At high doses (300-800 mg), it preferentially blocks postsynaptic dopamine D2 and D3 receptors in the limbic system, controlling positive symptoms of schizophrenia; at low doses (50 mg), it blocks presynaptic dopamine autoreceptors, increasing dopamine release to treat negative symptoms, dysthymia, and somatoform pain. Indicated for acute and chronic schizophrenia, dysthymic disorder, and management of chronic pain syndromes with psychosomatic components.